Literature DB >> 18346288

The unexpected discovery of a focus of hepatitis C virus genotype 5 in a Syrian province.

N Antaki1, M Haddad, K Kebbewar, J Abdelwahab, O Hamed, R Aaraj, N Alhaj, S Haffar, M Assil, M Ftayeh, F Assaad, D Doghman, T Ali, M Nasserelddine, A Ali, F Antaki.   

Abstract

Genotype 5 (G5) was initially discovered and is still mainly diagnosed in South Africa. No cases of G5 have ever been reported from the Middle East countries. The aim of the study was to determine the hepatitis C virus (HCV) genotype distribution in Syria and the prevalence of G5 in this country. Genotyping of HCV was performed in 636 consecutive HCV patients referred to eight medical centres in Syria over a 3-year period. Genotype 4 was the most frequent genotype (375 patients, 59%) followed by genotype 1 (181 patients, 28.5%) and G5 (64 patients, 10%). The majority of G5 patients (56 cases, 87%) live in the north of Syria, including 21 cases (33%) from Azaz, a small city close to Turkey. No obvious epidemiological reason for such high prevalence of G5 was found.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18346288     DOI: 10.1017/S095026880800054X

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  10 in total

Review 1.  Current status and emerging challenges in the treatment of hepatitis C virus genotypes 4 to 6.

Authors:  Vasilios Papastergiou; Stylianos Karatapanis
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

2.  HCV genotype distribution in Flanders and Brussels (Belgium): unravelling the spread of an uncommon HCV genotype 5a cluster.

Authors:  J Verbeeck; L Kwanten; F D'Heygere; A Beguin; S Michiels; I Desombere; G Leroux-Roels; P Lemey; F Nevens; M Van Ranst
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-09-10       Impact factor: 3.267

Review 3.  Hepatitis C virus infection in the Middle East and North Africa "MENA" region: injecting drug users (IDUs) is an under-investigated population.

Authors:  S Ramia; N M Melhem; K Kreidieh
Journal:  Infection       Date:  2012-01-12       Impact factor: 3.553

Review 4.  Epidemiology and treatment of hepatitis C genotypes 5 and 6.

Authors:  Khalid Al Naamani; Siham Al Sinani; Marc Deschênes
Journal:  Can J Gastroenterol       Date:  2013-01       Impact factor: 3.522

Review 5.  Epidemiology and natural history of HCV infection.

Authors:  Behzad Hajarizadeh; Jason Grebely; Gregory J Dore
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-07-02       Impact factor: 46.802

6.  Changes on Hepatitis C virus genotype distribution in Western Turkey: Evaluation of twelve-year data.

Authors:  Alev Çetin Duran; Özgül Kaya Çetinkaya; Ayça Arzu Sayıner; Gülşah Şeydaoğlu; Emre Özkarataş; Hakan Abacıoğlu
Journal:  Turk J Gastroenterol       Date:  2020-02       Impact factor: 1.852

Review 7.  The Epidemiology of Hepatitis C Virus in the Fertile Crescent: Systematic Review and Meta-Analysis.

Authors:  Hiam Chemaitelly; Karima Chaabna; Laith J Abu-Raddad
Journal:  PLoS One       Date:  2015-08-21       Impact factor: 3.240

Review 8.  Prevalence of Hepatitis C Virus Genotypes Among Patients in Countries of the Eastern Mediterranean Regional Office of WHO (EMRO): A Systematic Review and Meta-Analysis.

Authors:  Farzin Sadeghi; Mostafa Salehi-Vaziri; Amir Almasi-Hashiani; Mohammad Gholami-Fesharaki; Reza Pakzad; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-04-19       Impact factor: 0.660

9.  HCV Genotype Distribution of Patients with Chronic Hepatitis C in Istanbul.

Authors:  Mehmet Emin Bulut; Ummuhan Su Topalca; Ali Murat; Leyla Teke; Hazan Zengin Canalp; Murat Ocal; Banu Bayraktar
Journal:  Sisli Etfal Hastan Tip Bul       Date:  2021-03-17

Review 10.  The Distribution of Hepatitis C Virus Genotypes in Middle Eastern Countries: A Systematic Review and Meta-Analysis.

Authors:  Hossein Ghaderi-Zefrehi; Mohammad Gholami-Fesharaki; Heidar Sharafi; Farzin Sadeghi; Seyed Moayed Alavian
Journal:  Hepat Mon       Date:  2016-08-23       Impact factor: 0.660

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.